Inclusion Criteria : 
  1.  Male or female ≥ 18 years of age . 
  2.  Myasthenia Gravis Foundation of America ( MGFA ) Class II - IVa and likely not in need of a respirator for the duration of the study as judged by the Investigator . 
  3.  QMG score ≥ 12 at Screening and Baseline . 
Other , more specific inclusion criteria are defined in the protocol . 
Exclusion Criteria : 
  1.  Use of rituximab , belimumab , eculizumab or any monoclonal antibody for immunomodulation within 6 months prior to first dosing . 
  2.  Immunoglobulins given by SC , IV ( IVIG )  , or intramuscular route , or plasmapheresis / plasma exchange ( PE ) within 4 weeks before Screening . 
  3.  Thymectomy performed < 12 months prior to screening . 
  4.  Total IgG level < 6 g / L ( at screening )  . 
  5.  Absolute neutrophil count < 1500 cells / mm3 ( at screening )  . 
Other , more specific exclusion criteria are defined in the protocol